Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture.

Shogo Ozawa, Toshitaka Miura, Jun Terashima, Wataru Habano, Seiichi Ishida
{"title":"Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture.","authors":"Shogo Ozawa,&nbsp;Toshitaka Miura,&nbsp;Jun Terashima,&nbsp;Wataru Habano,&nbsp;Seiichi Ishida","doi":"10.2174/1872312814666201202112610","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In order to avoid drug-induced liver injury (DILI), in vitro assays, which enable the assessment of both metabolic activation and immune reaction processes that ultimately result in DILI, are needed.</p><p><strong>Objective: </strong>In this study, recent progress in the application of in vitro assays using cell culture systems is reviewed for potential DILI-causing drugs/xenobiotics and a mechanistic study on DILI, as well as on the limitations of in vitro cell culture systems for DILI research, was carried out.</p><p><strong>Methods: </strong>Information related to DILI was collected through a literature search of the PubMed database.</p><p><strong>Results: </strong>The initial biological event for the onset of DILI is the formation of cellular protein adducts after drugs have been metabolically activated by drug metabolizing enzymes. The damaged peptides derived from protein adducts lead to the activation of CD4<sup>+</sup> helper T lymphocytes and recognition by CD8<sup>+</sup> cytotoxic T lymphocytes, which destroy hepatocytes through immunological reactions. Because DILI is a major cause of drug attrition and drug withdrawal, numerous in vitro systems consisting of hepatocytes and immune/inflammatory cells or spheroids of human primary hepatocytes containing non-parenchymal cells have been developed. These cellular-based systems have identified DILI-inducing drugs, with approximately 50% sensitivity and 90% specificity.</p><p><strong>Conclusion: </strong>Different co-culture systems consisting of human hepatocyte-derived cells and other immune/inflammatory cells have enabled the identification of DILI-causing drugs and of the actual mechanisms of action.</p>","PeriodicalId":11339,"journal":{"name":"Drug metabolism letters","volume":"14 1","pages":"25-40"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872312814666201202112610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Background: In order to avoid drug-induced liver injury (DILI), in vitro assays, which enable the assessment of both metabolic activation and immune reaction processes that ultimately result in DILI, are needed.

Objective: In this study, recent progress in the application of in vitro assays using cell culture systems is reviewed for potential DILI-causing drugs/xenobiotics and a mechanistic study on DILI, as well as on the limitations of in vitro cell culture systems for DILI research, was carried out.

Methods: Information related to DILI was collected through a literature search of the PubMed database.

Results: The initial biological event for the onset of DILI is the formation of cellular protein adducts after drugs have been metabolically activated by drug metabolizing enzymes. The damaged peptides derived from protein adducts lead to the activation of CD4+ helper T lymphocytes and recognition by CD8+ cytotoxic T lymphocytes, which destroy hepatocytes through immunological reactions. Because DILI is a major cause of drug attrition and drug withdrawal, numerous in vitro systems consisting of hepatocytes and immune/inflammatory cells or spheroids of human primary hepatocytes containing non-parenchymal cells have been developed. These cellular-based systems have identified DILI-inducing drugs, with approximately 50% sensitivity and 90% specificity.

Conclusion: Different co-culture systems consisting of human hepatocyte-derived cells and other immune/inflammatory cells have enabled the identification of DILI-causing drugs and of the actual mechanisms of action.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体外细胞培养药物性肝损伤预测系统研究进展。
背景:为了避免药物性肝损伤(DILI),需要进行体外实验,以评估最终导致DILI的代谢激活和免疫反应过程。目的:综述了近年来体外细胞培养系统检测DILI的研究进展,并对DILI的机制进行了研究,同时对体外细胞培养系统用于DILI研究的局限性进行了综述。方法:通过PubMed数据库的文献检索收集DILI相关信息。结果:DILI发病的初始生物学事件是药物被药物代谢酶代谢激活后细胞蛋白加合物的形成。由蛋白质加合物产生的受损肽导致CD4+辅助性T淋巴细胞的激活和CD8+细胞毒性T淋巴细胞的识别,通过免疫反应破坏肝细胞。由于DILI是药物损耗和药物停药的主要原因,许多由肝细胞和免疫/炎症细胞或含有非实质细胞的人原代肝细胞球体组成的体外系统已经开发出来。这些基于细胞的系统已经鉴定出了dili诱导药物,大约有50%的敏感性和90%的特异性。结论:由人肝细胞源性细胞和其他免疫/炎症细胞组成的不同共培养系统能够鉴定导致dili的药物及其实际作用机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug metabolism letters
Drug metabolism letters Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
自引率
0.00%
发文量
12
期刊介绍: Drug Metabolism Letters publishes letters and research articles on major advances in all areas of drug metabolism and disposition. The emphasis is on publishing quality papers very rapidly by taking full advantage of the Internet technology both for the submission and review of manuscripts. The journal covers the following areas: In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites.
期刊最新文献
The role of plant-based products in the prevention of neurological complications. The Impact of the Coronavirus (COVID-19) Infection on the Drug-Metabolizing Enzymes Cytochrome P450s. ZY12201, A Potent TGR5 Agonist: Identification of a Novel Pan CYP450 Inhibitor Tool Compound for In-Vitro Assessment. Meet the Editorial Board Member Assessment of Prescribability and Switchability by Using Multiple Bioequivalence Assessment Approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1